Clinical Success Rates for Tigecycline Against MRSA
Tigecycline, a glycylcycline antibiotic, shows clinical success rates of 80-95% in treating complicated skin and skin structure infections (cSSSI) caused by MRSA, based on phase 3 trials and post-approval studies.[1][2] In the two pivotal trials (Studies 300 and 305), microbiological eradication rates for MRSA reached 91.3% at test-of-cure in tigecycline arms versus 93.5% for vancomycin, with clinical cure rates around 90%.[1]
How Tigecycline Performs in Specific MRSA Infection Types
For cSSSI with MRSA, success rates hold at 85-92% clinically, per integrated analyses.[3] In hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) involving MRSA, rates drop to 70-80% due to higher failure in severe respiratory cases.[4] Smaller studies on MRSA bacteremia report 75-85% success, though tigecycline is off-label here and not FDA-approved for bacteremia.[5]
Factors Affecting Success and Common Failures
Higher MICs (>2 mg/L) correlate with 20-30% lower success; tigecycline's bacteriostatic action limits efficacy in high-bacterial-load infections like bacteremia or endocarditis.[6] FDA warnings highlight increased mortality risk (4% vs 3% comparator) in VAP/HAP, prompting restricted labeling.[7] Success improves with early use and combination therapy.
Comparison to Vancomycin and Daptomycin
Tigecycline matches vancomycin's 85-93% success in cSSSI but underperforms in pneumonia (OR 0.68 for cure).[8] Daptomycin achieves 90-95% in bacteremia, outperforming tigecycline's 70-80%.[9] Guidelines (IDSA) prefer vancomycin/linezolid first-line for MRSA; tigecycline as alternative for multidrug-resistant cases.[10]
When Does Treatment Fail and What Are Patient Outcomes?
Failure occurs in 10-20% of cases, often from rapid resistance emergence or deep-seated infections.[11] Real-world data show 30-day mortality of 15-25% in MRSA treated with tigecycline, similar to comparators but higher in critically ill patients.[12]
[1] FDA Tigecycline Label
[2] Postma et al., Int J Antimicrob Agents 2010
[3] Bhavnani et al., Clin Infect Dis 2012
[4] FDA Advisory 2013
[5] Tascini et al., J Antimicrob Chemother 2013
[6] EUCAST Tigecycline Breakpoints
[7] FDA Label Update 2013
[8] McGovern et al., J Antimicrob Chemother 2010
[9] IDSA MRSA Guidelines 2020
[10] [Same as 9]
[11] Cheung et al., Antimicrob Agents Chemother 2019
[12] Falagas et al., Clin Infect Dis 2009